Conatus Pharmaceuticals (CNAT) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Conatus Pharmaceuticals (NASDAQ:CNAT) from a hold rating to a buy rating in a report issued on Saturday.

Several other research firms have also recently weighed in on CNAT. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, July 4th. Oppenheimer set a $14.00 price objective on shares of Conatus Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $12.50.

Conatus Pharmaceuticals stock opened at $6.49 on Friday. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $172.13 million, a price-to-earnings ratio of -10.64 and a beta of 1.39. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. The firm had revenue of $8.77 million for the quarter, compared to analyst estimates of $9.06 million. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%. sell-side analysts predict that Conatus Pharmaceuticals will post -0.61 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its position in Conatus Pharmaceuticals by 253.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 16,476 shares in the last quarter. Jane Street Group LLC purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $142,000. MYDA Advisors LLC purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $154,000. Wells Fargo & Company MN grew its position in Conatus Pharmaceuticals by 63.4% during the 1st quarter. Wells Fargo & Company MN now owns 55,600 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 21,564 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in Conatus Pharmaceuticals during the 2nd quarter worth approximately $311,000. Hedge funds and other institutional investors own 33.50% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Further Reading: Outstanding Shares and The Effect on Share Price

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply